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The use of a direct bronchial challenge test in primary care
to diagnose asthma
J. E. Bins1✉, E. I. Metting 2,3,4, J. B. Muilwijk-Kroes5, J. W. H. Kocks 3,6,7 and J. C. C. M. in ’t Veen1,8✉
Many asthmatics in primary care have mild symptoms and lack airflow obstruction. If variable expiratory airflow limitation cannot
be determined by spirometry or peak expiratory flow, despite a history of respiratory symptoms, a positive bronchial challenge test
(BCT) can confirm the diagnosis of asthma. However, BCT is traditionally performed in secondary care. In this observational real-life
study, we retrospectively analyze 5-year data of a primary care diagnostic center carrying out BCT by histamine provocation. In
total, 998 primary care patients aged ≥16 years underwent BCT, without any adverse events reported. To explore diagnostic
accuracy, we examine 584 patients with a high pretest probability of asthma. Fifty-seven percent of these patients have a positive
BCT result and can be accurately diagnosed with asthma. Our real-life data show BCT is safe and feasible in a suitably equipped
primary care diagnostic center. Furthermore, it could potentially reduce diagnostic referrals to secondary care.
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INTRODUCTION
Asthma is a one of the most common chronic conditions to be
dealt with in primary care. Worldwide it is estimated to affect 235
million people, with a prevalence ranging from 1 to 18% in
different countries1,2. According to recent data, 5.7% of the Dutch
population suffer from asthma3. Despite its high prevalence,
asthma can be challenging to diagnose, especially given that most
cases are diagnosed in primary care. This difficulty lies in the
variable nature of key features over time, such as airflow
obstruction and airway inflammation.
A diagnosis of asthma is made based on characteristic
respiratory symptoms—wheeze, shortness of breath, chest tight-
ness—and confirmed variable expiratory airflow limitation2.
However, many people with asthma, especially in primary care,
have mild symptoms and lack airflow obstruction4. Misdiagnosis
(both underdiagnosis and overdiagnosis) is therefore a problem
for both adults and children5,6. A factor that contributes to the
misdiagnosis of asthma is the poor diagnostic sensitivity of
spirometry, which cannot exclude asthma without further
investigation when results are inconclusive7. If variability in
expiratory airflow limitation cannot be determined by spirometry
or peak expiratory flow, but there is a history of variable chronic
respiratory symptoms, a positive bronchial challenge test (BCT)
can be used to confirm the diagnosis of asthma2,8. However,
currently in primary care settings, patients with normal spirometry
results but suspected asthma must be referred to secondary care
for BCT when the diagnosis remains unclear2. In the Netherlands,
the Star-shl Medical Diagnostic Centre in Rotterdam is the only
primary care diagnostic center to carry out direct BCTs by
histamine provocation.
The Global Initiative for Asthma provides the most widely used
strategy for the management of asthma. This suggests referral for
BCT to assess airway hyperresponsiveness when variable airflow
limitation—the key part of diagnosing asthma—cannot be
determined2. In the United Kingdom, there has been debate
about conflicting guidelines on the diagnosis and treatment of
asthma9. The National Institute for Health and Care Excellence
guideline advises additional testing with fractional exhaled nitric
oxide (FeNO) or BCT in cases of suspected asthma with normal
spirometry results10. However, the British Thoracic Society (BTS)/
Scottish Intercollegiate Guideline Network (SIGN) guideline states
that asthma is a clinical diagnosis that can be made based on a
typical history, without requiring a definitive diagnostic test11. In
contrast to these, the Dutch General Practitioner Society (Neder-
lands Huisartsen Genootschap [NHG]) advocates referral for a
direct provocation test or for consultation with a pulmonologist
when diagnostic uncertainty remains and, conflicting with the
BTS/SIGN guideline, clearly stating that inhaled corticosteroid (ICS)
therapy is only indicated when the diagnosis is certain12. None of
these guidelines gives recommendations for performing BCT
outside of a specialty care facility13.
Histamine and methacholine are the most used agents for “direct”
pharmacological BCT. Most published studies are based on
provocation with methacholine. The literature on histamine use is
scarce. The understandable fear of possible severe bronchoconstric-
tion has led to most authorities recommending that BCTs should
only be performed in specialist care facilities. However, to date,
thousands of methacholine challenge tests have been performed
without serious side effects14. Transient and mild symptoms are
common in patients with bronchial hyperresponsiveness (BHR),
including symptoms of wheeze, cough, dyspnea, and chest
tightness, though many experience no symptoms. Moreover,
delayed or prolonged responses to methacholine are rare8.
Direct BCT is used to increase or decrease the diagnostic
probability of asthma by determining if BHR is present at that
time. BHR is not an exclusive feature of asthma and can also
present in chronic obstructive pulmonary disease (COPD),
respiratory infections, and allergic rhinitis15. In general, testing
for BHR has high sensitivity and low specificity meaning that every
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BCT needs to be appropriately interpreted, taking into account not
only the test result but also the presenting symptoms and
history16. However, in patients with a high pretest probability of
asthma, a negative test result rules out asthma and a positive test
result can confirm the diagnosis of asthma8. In addition, the
probability that a positive BCT reflects asthma will increase the
lower the PD20 (provocative dose causing a 20% decline in forced
expiratory volume in 1 s (FEV1) from baseline)
17.
In this observational real-life study, we primarily aimed to
evaluate the feasibility and safety of direct BCT in a Dutch primary
care diagnostic center. We had two secondary aims: (1) to analyze
the characteristics of patients with a high probability of asthma
and to identify any predictors of a positive BCT in this group and
(2) to explore whether using BCT in primary care has the potential
to reduce diagnostic referrals to secondary care and the number
of asthma misdiagnoses.
RESULTS
Feasibility and safety
In total, 998 patients (n= 640 female, 64.1%) were identified who
had undergone a histamine provocation test at the diagnostic
center, equating to an average of 200 patients a year; among
these, BCT was deemed “not assessable” in 8 patients (<1%).
Throughout the retrospective study period, there were no
adverse events during BCT, and there was never a reason to
consult a doctor during or directly after BCT for such concerns.
Although the post-BCT FEV1 was required to return to ≥90% of
baseline, necessitating that bronchodilators were administered
when needed, only 4 patients (<1%) needed a bronchodilating
agent in addition to the salbutamol to recover to their baseline
FEV1. In each of these cases, the addition of ipratropium bromide
was enough to bring about recovery and allow them to go home
safely. Patients were advised to contact their general practitioner
(GP) whenever they would experience symptoms after leaving the
diagnostic center after the BCT. There were no GP consultations or
emergency department visits reported back to us. We did not
have direct access to data from these services, but as there is a
close connection between the diagnostic center and the referring
GPs, we find it very unlikely that in this 5-year time span any
serious side effects have taken place without us knowing.
Almost two-thirds of the total cohort (n= 645) had undergone
spirometry at the diagnostic center, including bronchodilator
testing, prior to BCT. The baseline characteristics of this final
cohort (n= 645) who underwent both spirometry and BCT at the
diagnostic center are shown in Table 1.
The indication for BCT was accurate in most patients, yet in 41
patients (6%) the indication for BCT was debatable. Based on the
results of spirometry and history, 27 patients already diagnosed
with asthma were referred for BCT. Most of these patients showed
borderline reversibility, but 4 showed reversibility of ≥12% and
≥200 mL and it is unclear why these were referred for BCT.
Another 14 patients were diagnosed with COPD before referral for
BCT. The indication for a BCT was not reported in these patients;
we assume asthma remained in the differential diagnosis due to a
fixed obstruction at spirometry.
Analysis of patients with high probability of asthma
Histamine provocation testing was positive in 376 (58%) of the
included participants in our final cohort of 645 patients (Table 1),
which was similar to the percentage in the overall study
population (574/998, 58%). All patients were given a working
diagnosis after spirometry, with 363 (56%) labeled as probable
asthma and 221 (32%) labeled as possible asthma (Fig. 1). These
584 patients comprised the cohort with a high pretest probability
of asthma. The details of the probable and possible asthma groups
are compared in Table 2.
Compared to the possible asthma group, those with probable
asthma were significantly younger (mean 41.04 ± 14.5 vs 46.01 ±
14.35 years, P < 0.001, Mann–Whitney U) and had an earlier
symptom onset (mean 30.98 ± 17.46 vs 37.81 ± 18.64, P < 0.001,
Mann–Whitney U). The probable asthma group also had
significantly higher mean reversibility after bronchodilation (BD;
FEV1 3.66% ± 4.03% vs 2.84% ± 3.39%, P= 0.013, t test) and higher
mean scores on the Asthma Control Questionnaire (ACQ; 1.52 ±
0.90 vs 1.15 ± 0.87, P < 0.001, Mann–Whitney U). Self-reported
allergies for pets and pollen were higher in the probable asthma
group (P= 0.010 and P= 0.007 respectively, and χ2). These
significant differences underpin why the probable asthma group
is more likely to have asthma than the possible asthma group.
In the probable asthma group, 223 patients (61.4%) experi-
enced bronchial hyperreactivity during BCT and were conse-
quently accurately diagnosed with asthma, while the absence of
hyperreactivity excluded asthma in the remaining 140 patients. In
the possible asthma group, another 110 patients (49.8%) had a
positive BCT result and were diagnosed with asthma, while the
diagnosis was excluded in the other half of this population.
Airflow obstruction post BD (FEV1/forced vital capacity (FVC)
post BD ≤70%) was detected in 43 patients (7%) of the final
cohort, suggesting either COPD or a fixed obstruction in asthma.
Of these patients, 72.1% (n= 31) had a positive BCT result. In the
group with a high pretest probability of asthma, 14 of the 22
patients (possible asthma= 13; probable asthma= 9) with airflow
obstruction post BD had a positive BCT result (64%).
A total of 217 patients were already using ICS when performing
BCT. Despite treatment with ICS, 77% (n= 133) of these patients
still had a positive BCT result. In the high probability group, this
percentage was lower; of the 183 patients on ICS, 103 patients
(56%) had a positive test result.
When comparing all patients by BCT result, there were few
significant differences between the 333 patients with positive
results (probable asthma= 223; possible asthma= 110) and the
251 patients with negative results (probable asthma= 140;
possible asthma= 111). Reversibility after BD was significantly
higher in the group with positive BCT results (mean 3.73% ±
3.94%) than in the group with negative BCT results (2.85% ±
3.60%, P= 0.006, t test). Although patients were slightly younger
in the positive BCT group (41.92 years) than in the negative BCT
group (44.24 years), the difference was not significant (P= 0.069,
Mann–Whitney U). Similarly, there was a non-significant difference
in question 6 on the ACQ (extra bronchodilator use), with the
positive BCT group scoring higher (mean 0.46 vs 0.31, P= 0.079,
Mann–Whitney U).
Diagnostic accuracy and diagnostic referrals
All 363 patients with probable asthma had typical histories of
asthma, but only 223 (61.4%) had bronchial hyperreactivity proven
by BCT. Half of the 221 patients with possible asthma had a
positive BCT, confirming asthma. In 251 patients with probable
and possible asthma, a negative BCT result meant that asthma
could be excluded (251/584, 43%).
Diagnostic referral to secondary care in this cohort could have
potentially been reduced by at least 333 patients (57%, 333/584)
who had a positive test confirming the diagnosis of asthma.
Patients with a negative test may still need referral to secondary
care whenever their respiratory symptoms remain unexplained.
This was the case for at least 42 patients with a negative BCT
result, since in the reports of their tests it was advised to consider
referral to a pulmonologist because the diagnosis was unclear.
Regression analysis
Using binary logistic regression, we analyzed whether there were
any predictors of a positive BCT result among patients with
probable and possible asthma. The cases are independent, the
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dependent variable is dichotomous, the data set is large (n= 645),
and there is no multicollinearity between the predictors. There is a
linear connection between independent variables and the log
odds. The initial univariate analysis showed that the following
variables were related to a positive BCT response with a
P value < 0.10: age, positive family history, ever smoked, seasonal
triggers, hyperreactivity for baking odors, allergy for pets,
wheezing (ACQ 5), use of bronchodilators (ACQ 6), age of onset,
reversibility, and the pre- and post-bronchodilator values for both
FEV1 and FEV1/FVC (% predicted) (Supplementary Table 1).
Therefore, these predictors were included in the log regression
analysis (Table 3).
The final logistic model showed that predictors having a self-
reported pet allergy (odds ratio (OR): 1.85; 95% confidence interval
(CI): 1.14–3.01) and using a bronchodilator (OR: 1.32; 95% CI:
1.05–1.65) were associated with an increased odds of a positive
bronchodilator response. By contrast, predictors that reduced the
odds of having a positive BCT result were being older (year) (OR:
0.97; 95% CI: 0.96–0.99) and having better lung function on both
the pre-bronchodilator FEV1 (liter) (OR: 0.99; 95% CI: 0.97–1.00)
and the post-bronchodilator FEV1/FVC (OR: 0.93; 95% CI:
0.91–0.96). The proportion of variation predicted by this model
was 12.5% (Nagelkerke R-squared).
DISCUSSION
In a literature search, we found no research into the use of direct
BCT as a diagnostic tool in primary care settings. Our analysis
shows that BCT by the histamine provocation test can be
performed safely and reliably in a primary care diagnostic center.
It was notable that the odds of having a positive BCT were
increased among younger patients, those with self-reported
pet allergy, those who used bronchodilators, and those with
poorer lung function. Looking at the of diagnoses made following
BCT, both rejecting and confirming asthma, we propose that BCT
in primary care has the potential to reduce the rates of both
misdiagnosis and referral to secondary care.
Although research by Aaron et al. has recently brought the issue
of asthma misdiagnosis to the fore, the underdiagnosis and
overdiagnosis is an ongoing global problem5,18–21. Misdiagnosis
may lead to inappropriate prescribing and an increased health
care use. In patients with a high probability of asthma, we showed
that adding a histamine provocation test to standard spirometry
Table 1. Baseline characteristics of patients undergoing spirometry
with bronchodilator response and BCT at the diagnostic center
(N= 645).
Variable Results Missing data
Age, mean ± SD (range) 43.24 ± 14.87
(16–76) years
n= 13
Age of onset, mean ± SD
(range)
33.3 ± 18.38 (0–71) years
Sex, n (%)
Male 231 (36%)
Female 414 (64%)
BMI, mean ± SD (range) 27.8 ± 5.52 (16–53) kg/m2 n= 1
Smoking
Never 359 (56%)
Previous 195 (30%)
Current 91 (14%)
Family history (asthma), n (%)
Positive 278 (44%)
Negative 291 (46%)
Unknown 76 (10%)
ACQ total, mean ± SD
(range)
1.37 ± 0.90 (0–4.83)
FEV1 in L, mean ± SD (range)
Pretest, L 3.08 ± 0.807 L
(1.49–5.96 L)
n= 12
% predicted 95.85% ± 13.04%
(67.5%–141.6%)
n= 13
Post-test, L 3.18 ± 0.84 L (1.62–6.17 L) n= 1
% predicted 99.02% ± 13.14%
(66–139%)
n= 1
FEV1/FVC %, mean ± SD (range)
Pre-BD 78.49 ± 7.80 (54.70–100) n= 12
Post-BD 81.61 ± 7.49 (54.45–100)
FEV1/FVC ≤ 70%, n (%)
Pre-BD 85 (13%)
Post-BD 43 (7%)
Reversibility %, mean ± SD
(range)
3.55% ± 4.0% n= 12
10–12% 16
≥12% 4
Reversibility in mL, in case
of ≥12%
372 ± 49.92 (320–440)
ICS use, n (%)
ICS mono 84 (13.0%)
ICS/LABA 133 (20.6%)
ICS total 217 (33.6%)
Antihistamine use, n (%)
Oral 81 (12.5%)
Nasal 55 (8.5%)
Ocular 3 (0.5%)
Self-reported allergy, n (%)
Pets 76 (12%)
Food 26 (4%)
Hay fever/seasonal 141 (22%)
Wheezing (ACQ5), n (%)
Yes 392 (61%)
No 253 (39%)
Table 1 continued
Variable Results Missing data
AB or prednisone ≥1 course last year, n (%)
No 449 (70%)
Yes 191 (30%)
Working diagnosis from spirometry, n (%)
Probable asthma 363 (56%)
Possible asthma (unclear) 221 (34%)
Asthma 27 (4%)
COPD 14 (2%)
Asthma/COPD 8 (1%)
No airflow obstruction 6 (1%)
Possible restriction 3 (0.5%)
Poor curve 3 (0.5%)
AB antibiotics, ACQ Asthma Control Questionnaire, BD bronchodilator, BMI
body mass index, COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, ICS inhalation
corticosteroid, LABA long-acting beta agonist, SD standard deviation.
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with bronchodilator response can increase diagnostic accuracy in
primary care. The addition of a BCT in the primary care setting can
help reject or confirm the diagnosis and may reduce misdiagnosis
rates. Indeed, when using methacholine, direct BCT has a
sensitivity of 98% for detecting asthma22. By contrast, Schneider
et al. showed that the sensitivity of simple spirometry was only
29% for diagnosing airway obstruction in asthma7, and data
showed that the sensitivity of primary care spirometry alone fell to
just 16% when diagnosing asthma. Given that normal spirometry
results do not rule out asthma, further investigation is needed in
patients who otherwise present with characteristic respiratory
symptoms.
In recent years, data have been published on the use of
combined asthma–COPD services in primary care23–27. These
services provide spirometry facilities, with all tests performed
being assessed by a pulmonologist who then gives the GP a
structured diagnostic and therapeutic assessment based on a
short history and the spirometry results27. These services have
proven helpful in diagnosing or excluding asthma, COPD, and
combined asthma and COPD in primary care. Implementing BCT in
these primary care diagnostic centers could further improve
diagnostic accuracy and reduce overtreatment. Instead of starting
a therapeutic trial of an ICS for 3 months, these centers could
perform BCT to confirm or exclude the diagnosis. Based on real-life
data from an asthma–COPD service in Groningen, the Nether-
lands, Metting et al. developed a diagnostic decision tree for
assessing obstructive lung disease28. Applying this decision tree to
our cohort of 645 patients would have resulted in 457 being
diagnosed with asthma and receiving a therapeutic trial of ICS.
However, only 272 of these patients had a positive BCT result, with
the remaining 185 having a negative result. By integrating BCT,
the risk of this overtreatment can be reduced while also ensuring
that alternative diagnoses are not missed. Manoharan et al. also
showed us that 30% of 123 patients with community managed
asthma in Scotland were potentially misdiagnosed or overtreated
as they were non-responsive to both methacholine and mannitol
challenge testing29.
We encountered no adverse events in our cohort, demonstrat-
ing the safety of direct histamine provocation testing in this
primary care diagnostic center in real-life conditions. This indicates
that BCT can be safely implemented in other primary care settings
if they are adequately equipped and staffed. The necessary safety
precautions, as outlined by the American Thoracic Society/
European Respiratory Society (ATS/ERS) guidelines, must be
guaranteed. Research has already shown that the BCT can be
used in primary care to monitor asthma treatment, with Turton
et al. concluding that the mannitol challenge test was feasible and
acceptable30. We therefore believe that there is growing evidence
for current guidelines to be adapted. In our opinion, BCT does not
necessarily have to take place in secondary care, it can now be
recommended in well-equipped primary care diagnostic centers.
Of course, this is contingent on ensuring that the indication for
BCT is appropriate, that spirometry is normal, that necessary
diagnostic symptoms and histories are available, and that the
results are assessed by a professional who is experienced in
interpreting pulmonary function tests (PFTs).
Current guidelines endorse referral for BCT to confirm or reject
the diagnosis of asthma whenever doubt remains unclear after
spirometry. In point of fact, positive and negative BCT results
contribute equally to diagnostic accuracy in patients with
respiratory symptoms14,17. Given these considerations, our data
indicate that diagnostic referrals to secondary care could be
dramatically reduced if more primary care diagnostic centers
started to provide BCT. Only those patients with unexplained
respiratory symptoms and a negative BCT result may still need
referral to secondary care, though this may not necessarily include
review by a pulmonologist. Other causes of respiratory symptoms
such as chest tightness and cough must also be considered.
Indeed, the GP who requested the PFTs must also consider other
possible causes, such as gastro-esophageal reflux or post-nasal
drip, or if they simply need to refer directly. Follow-up research
should clarify whether patients from our real-life cohort remain
labeled as non-asthmatic or are eventually labeled as having
asthma when referred to secondary care.
This was only a retrospective analysis of a real-life patient
cohort, and as such, we did not have all the data on patient
characteristics for the total cohort of 998 patients. That said, we
had all relevant data for the BCTs (i.e., results and side effects) and
near-complete data for the cohort who underwent both
spirometry and BCT. There was a notably good correlation when
comparing the characteristics of this group to other respiratory
patients in primary care26,29,31. All patients who underwent BCT at
the primary care diagnostic center had normal spirometry results
and were not initially referred to a pulmonologist by their GP.
Therefore, the cohort typically comprised patients with relatively
mild symptoms, which may have contributed to the lack of
adverse events during BCT. Nevertheless, we should point out that
there is a low incidence of adverse events with BCT in the
available literature8.
At the time of assessment, some patients were already using
inhaled medications due to the real-life design. In all cases, beta-
agonists and anti-muscarinic agents were stopped 6–48 h before
BCT, depending on their duration of action and the relevant ATS/
ERS guidelines. Antihistaminic drugs were stopped at least 72 h
before the test. Whenever a patient was using ICS, this was known
to the assessor and was taken into consideration when interpret-
ing the BCT results. Despite using an ICS, the majority of these
patients (77% in total cohort and 56% in patients in the high
probability asthma group) still had a positive BCT result. BHR to
histamine does not normalize when using ICS, at most the level of
severity may decrease by two doublings of the geometric mean
PD20
32,33. As we use a cut-off of >2.39 mg histamine to exclude
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allergy, night/morning symptons, 
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Spirometry with bronchodilator 
response
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nondiagnostic
No characteristic asthma
 features
Spirometry with bronchodilator 
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unclear
Fig. 1 Probable asthma and possible asthma groups. Flowchart showing how the probable asthma and possible asthma groups are
organized.
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BHR (corresponding with a provocative concentration causing a
20% fall in FEV1 (PC20) of 16 mg/mL), patients on ICS with a
negative BCT could almost certainly be labeled as not having
asthma. Nonetheless, in specific cases, when there was a notable
FEV1 reduction it was advised to repeat BCT after stopping ICS for
at least 4 weeks.
A small part of the final cohort (7%) showed airflow obstruction
post BD (FEV1/FVC ≤70%); in the high probability asthma group,
this was 4%. Despite this fixed obstruction, not all of these
patients showed BHR when tested. In these patients, the
differential diagnosis should be reconsidered, as there is evidence
of airway pathology. In these cases, it was recommended to repeat
BCT after at least 4 weeks (if applicable, after stopping inhalation
medication) or to refer to a pulmonologist.
Diagnosing asthma is challenging. Despite its utility, we
acknowledge that a BCT in a general population is not a gold
standard test for diagnosing or excluding asthma. The specificity
and sensitivity of a direct BCT for diagnosing asthma is strongly
dependent on the population being tested8,17. Perpiñá et al.
estimated that the optimal diagnostic value of methacholine
challenge testing occurs when the pretest probability of asthma is
30–70%34. In our final cohort, we only selected patients with a
high pretest probability of asthma. Consequently, in this selected
group with respiratory symptoms and suspected of asthma we
used the histamine provocation test as a tool to confirm or reject
asthma. Furthermore, direct challenge tests generally have a good
sensitivity to exclude current asthma in patients with respiratory
symptoms. Whether a patient had symptoms at the time of the
test was known to the assessor and was considered when
assessing the BCT results.
To date, the best combination of clinical features and diagnostic
tests has not been found. An alternative might be to use the
exhaled nitric oxide (FeNO) test, which can also contribute to an
accurate diagnosis of asthma35. Although there are no reports of
the FeNO test being used in primary care settings, if the BCT could
be routinely implemented with success, there may also be a valid
argument for implementing the FeNO test. Further research is
warranted on this point.
The real-life retrospective study design meant that we lacked a
control group against which to compare our results. If a
randomized controlled trial is performed to compare BCT in
primary and secondary care, we predict this will reach similar
conclusions with regards the safety, feasibility, and diagnostic
accuracy. Nevertheless, the strength afforded by prospective
research would reinforce the argument that BCT has a role in
primary care settings. Prospective research should ideally follow
the group of patients with respiratory symptoms, normal
spirometry, and a negative BCT who are referred to secondary
care to record the additional diagnostic steps and the final
diagnosis. To assess whether diagnostic referrals can be reduced, a
randomized trial should prospectively compare a cohort who
undergo BCT in primary care and another who are referred directly
to secondary care.
Our data in a real-life primary care setting indicate that
histamine provocation testing is feasible and safe. In our cohort,
we believe it improved the accuracy of asthma diagnosis.
Consequently, using BCT in primary care, in addition to spirometry
alone, has the potential to reduce the rates of asthma
misdiagnosis and the need for diagnostic referrals to secondary
care. We therefore recommend that the use of a BCT be
considered in well-equipped primary care laboratories as it
provides a valuable addition to spirometry with bronchodilator
response in the diagnostic work-up of patients with respiratory
symptoms.
Table 2. Possible asthma and probable asthma patient characteristics.
Variable Possible asthma,
N= 221
Probable
asthma, N= 363
P valuea
Age, mean ± SD (range) 46.01 ± 14.35
(16–76)
41.04 ± 14.85
(16–71)
0
Age of onset, mean ± SD
(range)
37.81 ± 18.64
(0–70)
30.98 ± 17.46
(0–71)
0
Sex, n (%)
Male 87 (39%) 120 (33%) 0.122
Female 134 (61%) 243 (67%)
BMI, mean ± SD 27.798 ± 4.99 kg/
m2
28.03 ± 5.95 kg/
m2
0.626
Smoking, n (%) 0.662
Never 131 (59%) 206 (57%)
Previous 64 (29%) 105 (29%)
Current 26 (12%) 52 (14%)
Medication use, n (%) 0.908
ICS mono 21 (10%) 52 (14%)
ICS/LABA 35 (16%) 75 (21%)
ICS total 56 (25%) 127 (35%)
Reversibility, mean ± SD 2.84% ± 3.39% 3.66% ± 4.03% 0.013
FEV1/FVC %, mean ± SD (range)
Pre-BD 78.46 ± 7.82
(54.70–99.47)
79.35 ± 7.12
(61.42–100)
0.179
Post-BD 81.11 ± 7.50
(55.83–99.41)
82.66 ± 6.58
(60.13–100)
0.016
FEV1/FVC ≤ 70%, n (%)
Pre-BD 27 (12%) 32 (9%) 0.286
Post-BD 13 (6%) 9 (2%)
Antihistamine use, n (%) 0.219
Oral 17 (8%) 57 (16%)
Nasal 14 (6%) 36 (10%)
Ocular 2 (1%) 1 (0.3%)
Self-reported allergy, n (%)
Pets 16 (7%) 52 (14%) 0.01
Food 7 (3%) 19 (5%) 0.24
Hay fever/seasonal 34 (15%) 90 (25%) 0.007
Wheezing (ACQ5) 0.000
Yes 110 (50%) 244(67%)
No 111 (50%) 119 (33%)
ACQ total, mean ± SD 1.1531 ± 0.87 1.52 ± 0.90 0.000
ACQ 1night 0.95 ± 1.21 1.40 ± 1.45 0.000
ACQ 2morning 1.30 ± 1.42 1.62 ± 1.38 0.000
ACQ 3activities 1.55 ± 1.18 1.93 ± 1.29 0.003
ACQ 4dyspnea 1.73 ± 1.31 2.25 ± 1.28 0.001
ACQ 5wheeze 1.08 ± 1.34 1.49 ± 1.42 0.000
ACQ 6med 0.30 ± 0.71 0.45 ± 0.84 0.016
AB/prednisone ≥1 course
last year, n (%)
0.215
Yes 74 (34%) 104 (29%)
No 145 (66%) 256 (71%)
Exacerbation/last year,
n (%)
0.3
0 160 (72%) 275 (76%)
1 40 (18%) 48 (13%)
≥2 21 (10%) 40 (11%)
AB antibiotics, ACQ Asthma Control Questionnaire, BD bronchodilator, BMI
body mass index, COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, ICS inhalation
corticosteroid, LABA long-acting beta agonist, SD standard deviation.
aFor comparing the two groups, we used t test for normally distributed
continuous variables or Mann–Whitney U test for continuous variables not
normally distributed. Chi-square test was used for nominal variables.
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METHODS
Study population
We conducted a real-life observational study at the Star-shl primary care
diagnostic center, Rotterdam, the Netherlands. GPs were free to refer
patients for diagnostic tests, including PFT. The center is licensed to carry
out spirometry with bronchodilator response and direct BCT as histamine
provocation testing. All PFTs are performed by qualified and certified
pulmonary function technologists, and the results are assessed by a
consulting pulmonologist or a GP with special interest in respiratory
medicine. We retrospectively analyzed data for all patients with respiratory
symptoms referred for diagnostic assessment by their GP between 2012
and 2017 if they were aged ≥16 years and underwent a histamine
provocation test. The patients were required to have respiratory symptoms
consistent with asthma in their differential diagnosis but without
significant airflow reversibility demonstrated by prior testing. Airflow
reversibility was defined as a change of ≥200mL and a ≥12% FEV1 post BD.
In this study, we used anonymous assessment data. According to Dutch
regulations, a separate ethics committee approval and informed consent
from human participants is not required, because routinely collected
health care data are used after anonymization.
Respiratory assessment at the primary care diagnostic center
At their first visit, spirometry was performed with bronchodilator
responsiveness according to ATS/ERS standard procedures36. All patients
who underwent spirometry were asked to complete a structured
questionnaire covering relevant clinical information (Fig. 2a), including
the ACQ, and the consulting pulmonologist or GP is provided with these
details and the spirometry results. Diagnostic assessment was then
reported on a standardized protocol (Fig. 2b), though comments could
be added if necessary, and the requesting GP was given a report of the
assessment. Wherever possible, a working diagnosis and therapeutic or
diagnostic recommendations (e.g., to perform BCT) were given without
seeing the patient. The following working diagnoses were given based on
the spirometry results: asthma, COPD, no airway obstruction, combined
asthma and COPD, probable asthma, possible asthma, possible restriction,
and patient could not perform test (Fig. 2b). “Probable asthma” referred to
patients with a typical history of asthma, but whose spirometry results
were not diagnostic. “Possible asthma” referred to patients without a
typical history of asthma, but whose spirometry results and symptoms
suggested that asthma remained possible (Fig. 1).
Bronchial challenge testing
BCT was performed by histamine provocation test. The primary endpoint
was a PD20, according to the most recent ERS guideline
8. The histamine
provocation test was only performed in patients who had already
undergone spirometry testing either at the diagnostic center or elsewhere.
BCT results were also assessed by an consulting GP or pulmonologist. The
assessment takes place chronologically; the assessor first assessed the
spirometry results; at a later time the BCT was assessed based on the test
results and short medical history and spirometry results from the first visit.
Table 3. Final regression model.
Variable B S.E. Wald df Sig. Exp(B) 95% CI for Exp(B)
Lower Upper
Age of the patient −0.03 0.01 13.70 1.00 0.00 0.97 0.96 0.99
Positive family history 0.31 0.17 3.28 1.00 0.07 1.37 0.98 1.91
Pet allergy 0.62 0.25 6.23 1.00 0.01 1.85 1.14 3.01
Frequency of bronchodilator use in the past week (ACQ6) 0.28 0.12 5.69 1.00 0.02 1.32 1.05 1.65
Reversibility in % 0.04 0.02 2.84 1.00 0.09 1.04 0.99 1.08
FEV1 pre in % −0.02 0.01 4.66 1.00 0.03 0.99 0.97 1.00
FEV1/FVC post in % −0.07 0.02 19.80 1.00 0.00 0.93 0.91 0.96
Constant 8.16 1.43 32.34 1.00 0.00 3481.36
ACQ Asthma Control Questionnaire, B beta, CI confidence interval, df degrees of freedom, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, S.E.
standard error, sig. significance.
Medical History Questionnaire
General information 
Age  
Sex 
Weight, height 
Symptoms  
Age of symptom onset  
Occupation & hobbies 
Medical family history 
Allergies 
Self-reported 
Smoking habits 
Never, previous, current 
Symptom scores 
ACQ
CCQ
Medication use 
Inhalation medication 
Oral, nasal, or ocular anti-allergy 
Exacerbations 
Prednisone or antibiotics use 
Comorbidities 
Spirometry Histamine provocation test (BCT) 
Curve  
— Assessable  
— Not assessable 
Spirometry 
— No obstruction 
— No obstruction, not reversible 
— Little obstruction, not reversible 
— Moderate obstruction, not reversible 
— Completely reversible obstruction 
— Difficult to assess 
FEV1 
— Threshold reached with 
symptom recognition 
— Threshold reached without 
symptom recognition 
— No relevant reduction in FEV1
— Reduction in FEV1, but 
threshold not reached  
— Not assessable 
Working diagnosis based on spirometry 
— Asthma 
— COPD 
— No airway obstruction  
— Combination of asthma/COPD 
(ACO)
— Probable asthma 
— Possible asthma (diagnosis unclear, 
asthma possible) 
— Possible restriction 
— Patient could not perform test   
If significant FEV1 reduction is present:  
Bronchial hyperreactivity: 
— Light 
— Moderate 
— Severe
a b
Fig. 2 Questionnaire items and structure of the PFT assessment. a Items on questionnaire before spirometry. b Format for structured PFT
assessment. ACQ Asthma Control Questionnaire, COPD Control Questionnaire, ACO asthma/COPD overlap, FEV1 forced expiratory volume in 1 s.
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The histamine dose itself was delivered using a 2-min tidal breathing
protocol, with a computer-controlled nebulizer (APS Pro for the JAEGER®
MasterScreen PFT Series) guaranteeing a reproducible inhaled dose and a
high-efficiency filter to eliminate the risk of cross-contamination. The
patients’ breathing pattern was displayed on a flow/time diagram to
control challenge substance inhalation within 2 min. The histamine
concentration was 32mg/mL and delivered at a starting dose of
0.05mg, with doses doubled in a stepwise manner based on flow/volume
curves to a maximum dose of 3.1 mg. Post-diluent FEV1 was assessed at
30 s and at 90 s after completing nebulization. The level of bronchial
hyperreactivity is then classified by the provocative histamine dose: severe,
<0.15mg; moderate, 0.15–0.60mg; mild, 0.60–2.39mg; and normal,
>2.39mg (Fig. 2a). If the FEV1 declined ≥20%, we administered 400 μg
salbutamol via a metered-dose inhaler with a valved holding chamber. If
the FEV1 failed to improve to ≥90% of the baseline FEV1, we first gave an
extra 200 μg salbutamol. If this was inadequate, we also gave 40 μg
ipratropium. The patient’s GP was informed, before discharge, in all cases
where the FEV1 did not return to ≥90% of the baseline level. If patients
experienced symptoms and the FEV1 did not decline, they were still given
400 μg of salbutamol.
Possible issues with test safety were mitigated by following the relevant
ATS/ERS guidelines. When performing BCT, a medical doctor was always
present in the building, and oxygen and medication were available in the
testing room to treat any cases of severe bronchoconstriction.
Feasibility, safety, and diagnostic value
A feasibility analysis was conducted in which we retrospectively looked at
the number of referrals, the correct indication of these referrals, the
number of BCTs carried out per year, and the quality of BCTs during the
studied 5-year period.
To analyze patients with a high probability of asthma, we only included
patients who performed a spirometry test at our diagnostic center before
undergoing BCT: the final cohort. This improved the chance of obtaining
consistent high-quality baseline spirometry results and working diagnoses
based on expert assessment. Furthermore, BCT was usually advised by the
expert assessor, so the indication for the test was assumed to be correct.
Patients labeled as probable or possible asthma were included because
these had a high pretest probability of asthma. We calculated how often
BCT was positive, thereby confirming the diagnosis of asthma.
Finally, we assessed the safety of BCT in the primary care diagnostic
center by looking at the adverse events during the test and that were
reported back to us after performing the test.
Statistical analysis
IBM SPSS Version 22 (IBM Corp., Armonk, NY, USA) was used for statistical
analysis. The baseline population characteristics were described by
descriptive statistics. We compared the baseline characteristics and
outcomes by t test or Mann–Whitney U test for continuous outcomes
and χ2 test for nominal outcomes. We used individual univariate regression
analysis to determine the relevant predictors for inclusion in the logistic
regression and included only those variables with a P value < 0.1. Binary
backward logistic regression was used to determine the characteristics
predicting a positive BCT test. Likelihood ratio tests were used for the
backward analyses. The raw values, ORs, and 95% CIs are presented, as
appropriate.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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